Recursion Pharmaceuticals

Industrialising drug discovery

Illustration of lines forming a number of circles centred around one point with may connecting lines.

What does it do?

Recursion combines artificial intelligence with automation to conduct experimental biology.

Why do we invest?

Recursion aims to change the pace and economics of drug discovery through machine learning and automation. Its primary skill is bringing together data scientists, biologists, and engineers in a rare example of effective collaboration. Its proprietary software underpins an entirely automated approach to running and analysing biological experiments, enabling it to conduct and learn from experimental biology at an unprecedented scale. Put simply, Recursion is automating the age-old practice of looking into a microscope and is replacing human interpretation with AI. This is exciting because it provides the opportunity to profitably pursue more minor diseases that may not have been commercially viable using traditional drug development processes.

Who is key?

Chris Gibson is the company’s Co-Founder and CEO. The culture he envisioned needed to feel different to enable people to let loose and be themselves. He believes that only then can they be creative and voice the wacky idea that could lead to something great. This culture does not strike us as merely a perk but rather a sign of an intentional and thought-through effort to create cohesion and a shared sense of direction.


Founded in: 2013

Invested in: 2019

Went public: 2021


Headquartered: U.S.

Important information

The company showcased on this page is part of a diversified portfolio. The commentary should not be taken as advice on an individual stock.

Investment trusts are UK public companies and are not authorised and regulated by the Financial Conduct Authority. You may not get back the amount invested and please bear in mind that past performance is not a guide to future performance.